Centre Hospitalier Universitaire Grenoble Alpes
Centre Hospitalier Universitaire Grenoble Alpes is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
MInimal residual Disease Adapted Strategy / IFM 2020-02: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group IFM
Sponsor Intergroupe Francophone Du Myelome
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-demand Treatment of Angioedema Attacks in Adults with Acquired Angioedema due to C1 Inhibitor Deficiency
Sponsor Pharvaris Netherlands B.V.
- Start (EU)
- Latest update
- Estimated end
Local and systemic safety and tolerability of ascending doses of TOP-N53, a nitric oxide (NO)-releasing phosphodiesterase-5 (PDE5) inhibitor, administered topically, on wound in patients with digital ulcers (DU) in systemic sclerosis (SSc) in an open-label, vehicle-controlled, phase 2a, multi-center clinical trial
Sponsor Topadur Pharma Deutschland GmbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Centre Hospitalier Universitaire Grenoble Alpes?
The 2026-10-09 snapshot links Centre Hospitalier Universitaire Grenoble Alpes to 3 distinct CTIS trials. Recorded services include Laboratory services, LSCI central reading, Medical expertise, Safety reporting & pharmacovigilance. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Centre Hospitalier Universitaire Grenoble Alpes?
The most frequently recorded therapeutic areas are Immunology, Allergy, Dermatology, Haematological Malignancies. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Centre Hospitalier Universitaire Grenoble Alpes conducted?
The linked trials record locations in 10 countries, including France, Austria, Belgium, Bulgaria, Germany. These are trial locations, not confirmed office locations or countries where Centre Hospitalier Universitaire Grenoble Alpes delivered services.
What can this page tell me about Centre Hospitalier Universitaire Grenoble Alpes's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Centre Hospitalier Universitaire Grenoble Alpes. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Centre Hospitalier Universitaire Grenoble Alpes